Condition
Multiple Drug Use
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 1 (1)
P 4 (1)
Trial Status
Completed3
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06324786Not ApplicableRecruitingPrimary
Brain Mechanisms of Reducing Polysubstance Use
NCT04261504Not ApplicableCompletedPrimary
Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention
NCT06214130Phase 1CompletedPrimary
Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets
NCT01758679Phase 4UnknownPrimary
A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma
NCT01689493Not ApplicableCompleted
Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation
Showing all 5 trials